Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

PURPOSE: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Nancy U., Borges, Virginia, Anders, Carey, Murthy, Rashmi K., Paplomata, Elisavet, Hamilton, Erika, Hurvitz, Sara, Loi, Sherene, Okines, Alicia, Abramson, Vandana, Bedard, Philippe L., Oliveira, Mafalda, Mueller, Volkmar, Zelnak, Amelia, DiGiovanna, Michael P., Bachelot, Thomas, Chien, A. Jo, O’Regan, Ruth, Wardley, Andrew, Conlin, Alison, Cameron, David, Carey, Lisa, Curigliano, Giuseppe, Gelmon, Karen, Loibl, Sibylle, Mayor, JoAl, McGoldrick, Suzanne, An, Xuebei, Winer, Eric P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403000/
https://www.ncbi.nlm.nih.gov/pubmed/32468955
http://dx.doi.org/10.1200/JCO.20.00775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403000/
https://www.ncbi.nlm.nih.gov/pubmed/32468955
http://dx.doi.org/10.1200/JCO.20.00775

Ejemplares similares